Authors : Dr. Camilo Vidal Araya; Dr. María José Yarí Acosta; Dr. Amanda Oraa

Volume/Issue : Volume 10 - 2025, Issue 7 - July

Google Scholar : https://tinyurl.com/3hh5wtjm

Scribd : https://tinyurl.com/3p4346cs

DOI : https://doi.org/10.38124/ijisrt/25jul1494

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Introduction: Atrial fibrillation represents one of the most frequent arrhythmias in emergency services, particularly in settings with limited resources where clear protocols and accessible drugs are required. Verapamil shows significant potential for controlling ventricular rate, although it faces various implementation challenges. This study systematically evaluates its efficacy, safety, and feasibility in emergency contexts with limited resources.  Methods: A systematic review was conducted following PRISMA guidelines. The search was performed in MEDLINE/PubMed, Embase, Cochrane Library, LILACS, and Google Scholar (January 2000-June 2024), including observational studies, clinical trials, and economic evaluations. Specific MeSH terms related to verapamil and atrial fibrillation in emergencies were used. Two independent reviewers assessed methodological quality using GRADE and Newcastle-Ottawa scales.  Results: Of 487 articles identified, 42 met inclusion criteria. Verapamil demonstrated efficacy in ventricular rate control (mean reduction of 25-35 bpm in 30 minutes) with a favorable safety profile (NNH for significant hypotension: 38). Structured protocols reduced hospital admissions (18%, p<0.01) and need for cardioversions (22%, p<0.005) without requiring additional personnel. Economic analyses showed cost reduction ($420-680 per patient) by reducing admissions and hospital stays. "Wait and see" strategies proved viable in selected patients (CHA2DS2-VASc <2, without ventricular dysfunction).  Discussion: The findings demonstrate that verapamil, when implemented within structured protocols, represents an effective alternative for ventricular rate control in atrial fibrillation in emergency services. Its favorable safety profile, with a number needed to harm (NNH) of 38 for significant hypotension, suggests a manageable risk in controlled settings. The significant reductions in hospital admissions and need for cardioversions have important implications for healthcare systems with limited resources, where resource optimization is crucial. Additionally, the documented economic benefits reinforce its value as a cost-efficient intervention.  Conclusions: Verapamil constitutes an effective, safe, and cost-efficient option for the management of atrial fibrillation in emergency settings with limited resources when implemented within structured protocols. It is recommended to develop standardized guidelines, improve transition to outpatient care, and conduct larger comparative studies to optimize its use in various clinical contexts.

Keywords : Atrial Fibrillation, Verapamil, Emergency Services, Limited Resources, Rate Control.

References :

1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498.
2. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-47.
3. Rozen G, Hosseini SM, Kaadan MI, Biton Y, Heist EK, Vangel M, et al. Emergency Department Visits for Atrial Fibrillation in the United States: Trends in Admission Rates and Economic Burden From 2007 to 2014. J Am Heart Assoc. 2018;7(15):e009024.
4. Cubillos L, Haddad A, Kuznik A, Mould-Quevedo J. Burden of disease from atrial fibrillation in adults from seven countries in Latin America. Int J Gen Med. 2014;7:441-8.
5. Coll-Vinent B, Martín A, Sánchez J, Tamargo J, Suero C, Malagón F, et al. Benefits of Emergency Departments' Contribution to Stroke Prophylaxis in Atrial Fibrillation: The EMERG-AF Study (Emergency Department Stroke Prophylaxis and Guidelines Implementation in Atrial Fibrillation). Stroke. 2017;48(5):1344-52.
6. Hsia RY, Mbembati NA, Macfarlane S, Kruk ME. Access to emergency and surgical care in sub-Saharan Africa: the infrastructure gap. Health Policy Plan. 2012;27(3):234-44.
7. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125-e151.
8. Rogenstein C, Kelly AM, Mason S, Schneider S, Lang E, Clement CM, et al. An international view of how recent-onset atrial fibrillation is treated in the emergency department. Acad Emerg Med. 2012;19(11):1255-60.
9. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962.
10. Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2020;36(12):1847-948.
11. Delle Karth G, Geppert A, Neunteufel T, Priglinger U, Haumer M, Gschwandtner M, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med. 2001;29(6):1149-53.
12. Salerno DM, Dias VC, Kleiger RE, Tschida VH, Sung RJ, Sami M, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. The Diltiazem-Atrial Fibrillation/Flutter Study Group. Am J Cardiol. 1989;63(15):1046-51.
13. Demircan C, Cikriklar HI, Engindeniz Z, Cebicci H, Atar N, Guler V, et al. Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation. Emerg Med J. 2005;22(6):411-4.
14. Fromm C, Suau SJ, Cohen V, Likourezos A, Jellinek-Cohen S, Rose J, et al. Diltiazem vs. Metoprolol in the Management of Atrial Fibrillation or Flutter with Rapid Ventricular Rate in the Emergency Department. J Emerg Med. 2015;49(2):175-82.
15. Martindale JL, deSouza IS, Silverberg M, Freedman J, Sinert R. β-Blockers versus calcium channel blockers for acute rate control of atrial fibrillation with rapid ventricular response: a systematic review. Eur J Emerg Med. 2015;22(3):150-4.
16. Scheuermeyer FX, Andolfatto G, Christenson J, Villa-Roel C, Rowe B. A multicenter randomized trial to evaluate a chemical-first or electrical-first cardioversion strategy for patients with uncomplicated acute atrial fibrillation. Acad Emerg Med. 2019;26(9):969-81.
17. Barbic D, DeWitt C, Harris D, Stenstrom R, Grafstein E, Wu C, et al. Implementation of an emergency department atrial fibrillation and flutter pathway improves rates of appropriate anticoagulation, reduces length of stay and thirty-day revisit rates for congestive heart failure. CJEM. 2018;20(3):392-400.
18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
19. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
20. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [Internet]. [cited 2024 Jun 15]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
21. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ. 2013;346:f1049.
22. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.
23. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-6.
24. Fromm C, Suau SJ, Cohen V, Likourezos A, Jellinek-Cohen S, Rose J, et al. Diltiazem vs. Metoprolol in the Management of Atrial Fibrillation or Flutter with Rapid Ventricular Rate in the Emergency Department. J Emerg Med. 2015;49(2):175-82.
25. Stiell IG, Sivilotti MLA, Taljaard M, Birnie D, Vadeboncoeur A, Hohl CM, et al. Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial. Lancet. 2020;395(10221):339-49.
26. Barbic D, DeWitt C, Harris D, Stenstrom R, Grafstein E, Wu C, et al. Implementation of an emergency department atrial fibrillation and flutter pathway improves rates of appropriate anticoagulation, reduces length of stay and thirty-day revisit rates for congestive heart failure. CJEM. 2018;20(3):392-400.
27. Vinson DR, Hoehn T, Graber DJ, Williams TM. Managing Emergency Department Patients With Recent-Onset Atrial Fibrillation. J Emerg Med. 2012;42(2):139-48.
28. Marill KA, Gauharou ES, Nelson BK, Peterson MA, Curtis RL, Gonzalez MR. Prospective, randomized trial of template-assisted versus undirected written recording of physician records in the emergency department. Ann Emerg Med. 1999 May;33(5):500-9.
29. Costantino G, Podda GM, Falsetti L, Iannone P, Lages A, Marra AM, et al. Guidelines on the management of atrial fibrillation in the emergency department: a critical appraisal. Intern Emerg Med. 2017;12(6):769-76.
30. Baugh CW, Clark CL, Wilson JW, Stiell IG, Kocheril AG, Luck KK, Myers TD, Pollack CV Jr, Roumpf SK, Tomassoni GF, Williams JM, Patel BB, Wu F, Pines JM. Creation and Implementation of an Outpatient Pathway for Atrial Fibrillation in the Emergency Department Setting: Results of an Expert Panel. Acad Emerg Med. 2018 Sep;25(9):1065-1075.